Regenerative Medicine Market Size, Share & Trends Analysis By Product (Primary Cell-based, Stem & Progenitor Cell-based), By Therapeutic Category (Dermatology, Oncology) And Segment Forecasts, 2019 - 2025

Report Overview

The global regenerative medicine market size was estimated at USD 2.60 million in 2018 and is expected to witness a CAGR of 11.6% throughout the forecast period. A strong product pipeline in clinical trials and the presence of government and private funding to support research is anticipated to boost the growth. A robust pipeline is indicative of the high potential of products in the future. The companies are investing heavily in R&D to upgrade their products with the latest technology and to cater to the unmet consumer needs. Key players are investigating and developing pipeline products for diabetes and neurological disorders, cancers, and cardiovascular diseases owing to the high prevalence of these diseases.

The presence of several programs and continuous investments by government and private agencies to support R&D also accelerates the industry's progress. For instance, the National Institutes of Health (NIH) supports the scientific research community through NIH Regenerative Medicine Program, NIH Stem Cell Libraries & Projects, NIH Stem Cell Unit, and others.

Similarly, initiatives by market players to raise finance for R&D of regenerative medicine are anticipated to support the growth of the regenerative medicine market. Also, companies are collaborating to strengthen their R&D capabilities to develop and commercialize innovative therapies to ensure their availability to their customers locally or worldwide.

For instance, in March 2018, SanBio Group signed an agreement with Hitachi Chemical Advanced Therapeutics Solutions, LLC for the development and contract manufacturing of regenerative medicines. In September 2018, Key Biologics LLC announced an agreement with Blood Centers of America to support research and product development for cell therapy.

Technological advancements in stem cell-based therapies have revolutionized the perspective of researchers toward regenerative medicine. Advances in stem cell therapy have accelerated the developments in regenerative medicine. For instance, haematogenic stem cells are currently being used for the treatment of leukemia and blood disorders.

Product Insights

The therapeutics segment held the maximum revenue share in 2018 and is anticipated to continue its dominance throughout the forecast period. Within therapeutics vertical, primary cell-based therapies are the most developed therapeutics available due to their usage for different indications and their early adoption in clinical application.

Stem cell and progenitor cell-based therapies segment are expected to register the fastest CAGR during the forecast period due to high investments in stem cell research coupled with redrafting in regulatory policies for their use in clinical applications. Allogenic stem cell-based therapies are estimated to account for the largest revenue share whereas autologous therapies are projected to witness the fastest CAGR over the forecast period.

Key vendors with specialized technology provide management, manufacturing, characterization, engineering, and quality control services along with other facilities for clinical trials and other research associated with the development of regenerative therapies. Hence, with the rise in R&D and clinical trials of regenerative medicines, the services segment is projected to witness rapid growth.

Therapeutic Category Insights

Dermatology led the therapeutic category in terms of revenue generation in 2018. Factors attributed to this largest share include the availability of easy grafting methodologies for skin diseases and wounds. A significant number of Food and Drug Administration (FDA) approved wound healing products are present for clinical applications for decades.

Also, various novel approaches in developmental phases promote tissue engineering. This includes the use of biomaterials and drug delivery systems, which stimulate and control the immune system and influence cell replication. Increased complexity of the wound healing process with severe diseases such as diabetes and HIV has encouraged R&D activities in this segment.

The oncology segment is anticipated to witness the fastest CAGR over the forecast period. A high prevalence of cancer has resulted in the implementation of efficient cancer treatment options. Various government organizations as well as private companies have made high investments in cancer research and development of regenerative & advanced cell therapies. Global efforts to reduce the cancer burden are anticipated to support the lucrative growth of the oncology segment.

Regional Insights

North America held the leading market share in terms of revenue in 2018 due to the presence of a significant number of key players based in U.S. Moreover, availability of advanced technologies and presence of research institutes involved in the development of novel therapeutics is attributive to the high number of clinical trials in this region.

Availability of funds as well as rising initiatives by government and private organizations contributes to the highest revenue flow from the U.S. For instance, the “2020: A New Vision” initiative of the U.S. Department of Health and Human Services recognizes regenerative medicine at the forefront of healthcare.

The Asia Pacific is predicted to witness exponential growth over the forecast period owing to the expansion of infrastructure and facilities to accelerate stem cell research in the emerging regional economies. In Japan, the Ministry of Health, Labor, and Welfare approved Regenerative Medicine law in April 2013, which propelled the clinical development of regenerative and cell-based therapies.

Similarly, the Chinese government has approved much research related to human embryonic stem cells that have encouraged researchers to explore the clinical potential of these cells in China. Apart from this, the rising medical needs of the people, changing lifestyle, and an aging population are other factors positively influencing regional growth.

Key Companies & Market Share Insights

Key vendors leading this market include Integra LifeSciences Corporation; MiMedx Group, Inc.; AstraZeneca; F. Hoffmann-La Roche Ltd; Merck & Co., Inc.; Pfizer Inc.; and Baxter. This is owing to high investments contributed by these firms for the development of regenerative therapies to meet the demand for unmet clinical needs.

The market is highly competitive as the companies are focusing on the introduction of therapies for oncology and age-related degenerative disorders. Moreover, collaborative efforts and strategic agreements for product development and technology sharing are expected to expand the market scope.

Regenerative Medicine Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2025. For this study, Grand View Research has segmented the global regenerative medicine market report based on product type, therapeutic category, and region:

• Product Type Outlook (Revenue, USD Million, 2014 - 2025)

  • Therapeutics

    • Primary Cell-bases Therapeutics

      • Dermatology

      • Musculoskeletal

      • Surgical

      • Dental

      • Others

    • Stem Cell & Progenitor Cell-based Therapeutics

      • Allogeneic

      • Autologous

      • Others

    • Cell-based Immunotherapies

    • Gene Therapies

  • Tools

  • Banks

  • Services

• Therapeutic Category Outlook (Revenue, USD Million, 2014 - 2025)

  • Dermatology

  • Musculoskeletal

  • Immunology & Inflammation

  • Oncology

  • Cardiovascular

  • Ophthalmology

  • Others

• Regional Outlook (Revenue, USD Million, 2014 - 2025)

  • North America

    • The U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

  • Asia Pacific

    • China

    • Japan

  • Latin America

    • Brazil

  • Middle East & Africa

    • South Africa